Login to Your Account


Prevents disease progression

LONDON – Medday Pharmaceuticals SAS reported its phase III trial of MD1003 in progressive multiple sclerosis has met the challenging primary endpoint of improving mobility, with 12.6 percent (p = 0.051) of patients showing an improvement in either the Expanded Disability Status Score or a timed 25-foot walk, after nine months of treatment. more »


Opinion


Partners in Focus